LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy

Inclusion criteria 1. Meet the clinical confirmed diagnostic criteria of "diabetic peripheral neuropathy"; 2. Toronto score ≥ 6 points; 3. Meet the Chinese medicine diagnostic criteria of Pi-Shen-Liang-Xu (Deficiency of Pi and Shen) and Yu-Re-Ru-Luo (Collaterals with Stasis and Heat） Zheng (Syndrome) in diabetic peripheral neuropathy; 4. Over 18 years old and under 75 years old, regardless of gender and ethnicity; 5. Have received basic treatment for diabetes controled with stable blood glucose level (fasting blood glucose: \<7mmol / L; 2h postprandial blood glucose: \<11.1mmol / L; glycated hemoglobin: \<8%); 6. Have not taken or stopped taking DPN-related drugs (Mutan granules, Qidan Tongluo granules, pregabalin, duloxetine, etc.) for more than one week; 7. Sign the informed consent form with valid telephone contact information. Exclusion criteria 1. Patients with diabetic ketosis, ketoacidosis or co-infection; 2. Patients with known malignant tumors; 3. Patients with known severe brain diseases, as cerebral infactions with limited activity； 4. Patients with known severe arrhythmias or heart failure over Grade 2 (New York Heart Association), or other known severe heart diseases; 5. Patients with known severe kidney impairment (creatinine ≥200ummol/L); 6. During the screening or within 24 hours before screening, patients were found to have any of the following laboratory parameter abnormalities (based on local laboratory reference range):-ALT and/or AST level\> 2 times the upper limit of normal range (ULN); 7. Patients with spinal cord injury, cervical and lumbar spine lesions (nervous root compression, spinal stenosis, cervical and lumbar degenerative lesions) or sequelae of cerebrovascular disease, neuromuscular junction or muscle disease; 8. Patients with other neuropathy diseases caused by, such as: cerebral infarction, Guillain-Barre syndrome, severe arteriovenous vascular disease (venous embolism, lymphangitis), chronic inflammatory demyelinating polyneuropathy, VitB Deficiency, hypothyroidism, alcoholism, neurotoxicity indused by chemotherapeutic drugs, or metabolic nerve damage caused by renal insufficiency; 9. Patients with severe arteriovenous vascular disease (venous embolism, lymphangitis, etc.); 10. Patients with epilepsy or mental illness; 11. Alcoholics; 12. Patients with a history of psychotropic substance abuse; 13. Patients with allergies or allergies to any drugs in the trial; 14. pregnant women or patients with intention to become pregnant; 15. Participated in other clinical trials in the past 1 month; 16. Patients would not take drug continuously which could affect the evaluation of efficacy; 17. Investigator evaluates as unsuitable to participate in this clinical trial.